

Dextromethorphan qualification report

esqLABS GmbH

2023-08-18

Table of Content

1	Introduction	3
2	Methods	3
2.1	Software	3
2.2	Drug-gene-interaction	3
2.3	Qualification process	3
2.4	Consolidation of expression profiles	3
3	Results	3
4	Conclusion	18
	References	18

i Note

This report has been created with simulation results loaded from results folder 2023-07-21 12-59 .

1 Introduction

This document describes the qualification of a published dextromethorphan physiologically-based pharmacokinetics (PBPK) model for the use with the Open Systems Pharmacology Software (OSPS) Version 11.2.

The PBPK model has been developed with OSPS version 9.1 and published by ([Rüdesheim et al. 2022](#)). Model snapshots have been downloaded on 16.06.2023 from the Open Systems Pharmacology (OSP) [repository](#). As of 16.06.2023, no model version qualified for OSP version 11.2 is publicly available.

2 Methods

2.1 Software

For recreating the original results from the publication, OSPS [version 9.1](#) was used. The qualification is done with OSPS [version 11.2.142](#).

2.2 Drug-gene-interaction

The model is intended to be used in drug-drug interactions (DDI) simulations with dextromethorphan as a CYP2D6 victim. Drug-gene interactions (DGI) to describe variabilities of CYP2D6 activity are modeled as variations of the catalytic rate constant k_{cat} . Following values are used in the project:


2.3 Qualification process

2.4 Consolidation of expression profiles


3 Results

Comparison of time-concentration profiles generated with the different software versions are presented in the following:


Antecip Bioventures EM, 60 mg dextromethorphan hydrobromide multiple dose (capsule/solution),
n=10 - time profile




Armani 2017 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=20 - time profile




Capon 1996 EM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=6 - time profile




Capon 1996 PM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=6 - time profile




Duedahl 2005 EM, 0.5 mg/kg dextromethorphan base (infusion), n=24 - time profile




Dumond 2010 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=23 - time profile




Edwards 2017 EM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=48 - time profile




Ermer 2015 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=30 - time profile




Feld 2013 EM, 60 mg dextromethorphan hydrobromide (capsule/solution), n=17 - time profile




Gazzaz 2018 NM, 30 mg dextromethorphan hydrobromide (cocktail), n=30, AS=1.25 - time profile




Gorski 2004 EM, 30 mg dextromethorphan hydromide (capsule/solution), n=11 - time profile




Gorski 2004 PM, 30 mg dextromethorphan hydromide (capsule/solution), n=1 - time profile




Kakuda 2014 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=14 - time profile




Khalilieh 2018 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=20 - time profile




Nakashima 2007 EM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=24 - time profile




Nyunt 2008 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=12 - time profile




Q116_PO_15_DEX_SD_PVB_EM_126-Dextromethorphan-Peripheral Venous Blood-Plasma-[ng/mL] v9.1 - time profile




Q116_PO_15_DEX_SD_PVB_EM_125-Dextromethorphan-Peripheral Venous Blood-Plasma-[ng/mL] v9.1 - time profile




Qiu 2016 NM, 15 mg dextromethorphan hydrobromide (capsule/solution), n=6, AS=2 - time profile




Sager 2014 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=10 - time profile




Schadel 1995 EM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=5 - time profile




Schadel 1995 PM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=4 - time profile




Stage 2018 EM, 30 mg dextromethorphan hydrobromide (cocktail), n=12 - time profile




Storelli 2018 IM, 5 mg dextromethorphan base (capsule/solution), n=16 - time profile




Storelli 2018 NM, 5 mg dextromethorphan base (capsule/solution), n=17, AS=2 - time profile




Tennezé 1999 EM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=36 - time profile




Yamazaki 2017 IM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=12, AS=0.5 -
time profile



Yamazaki 2017 NM, 30 mg dextromethorphan hydrobromide (capsule/solution), n=11, AS=2 -
time profile



Zawertailo 2009 NM, 3 mg/kg dextromethorphan hydrobromide (capsule/solution), n=6, AS=2 - time profile



4 Conclusion

References

Rüdesheim, Simeon, Dominik Selzer, Uwe Fuhr, Matthias Schwab, and Thorsten Lehr. 2022. "Physiologically-Based Pharmacokinetic Modeling of Dextromethorphan to Investigate Interindividual Variability Within CYP2D6 Activity Score Groups." *CPT: Pharmacometrics & Systems Pharmacology* 11 (4): 494–511. <https://doi.org/10.1002/psp4.12776>.